| Log IL-6 (pg/ml) | ||||
| Intent-to-treat analysis | ||||
| Time | 0.01 | 0.04 | 0.13 | 0.897 |
| Main effect of group | 0.04 | 0.12 | 0.34 | 0.738 |
| Group × time interaction | −0.03 | 0.06 | −0.46 | 0.645 |
| Per-protocol analysis | ||||
| Time | 0.03 | 0.04 | 0.62 | 0.533 |
| Main effect of group | 0.00 | 0.15 | −0.01 | 0.990 |
| Group × time interaction | −0.02 | 0.06 | −0.36 | 0.716 |
| IL-12 p70 (pg/ml) | ||||
| Intent-to-treat analysis | ||||
| Time | −0.18 | 0.08 | −2.16 | 0.033 |
| Main effect of group | −0.09 | 0.57 | −0.17 | 0.869 |
| Group × time interaction | 0.06 | 0.12 | 0.52 | 0.602 |
| Per-protocol analysis | ||||
| Time | −0.17 | 0.09 | −1.90 | 0.059 |
| Main effect of group | −0.13 | 0.46 | −0.29 | 0.774 |
| Group × time interaction | 0.07 | 0.12 | 0.55 | 0.587 |
| ANTI-INFLAMMATORY | ||||
| Log IL-1ra (pg/ml) | ||||
| Intent-to-treat analysis | ||||
| Time | −0.04 | 0.05 | −0.78 | 0.436 |
| Main effect of group | 0.06 | 0.19 | 0.33 | 0.741 |
| Group × time interaction | 0.05 | 0.07 | 0.78 | 0.436 |
| Per-protocol analysis | ||||
| Time | −0.05 | 0.06 | −0.89 | 0.377 |
| Main effect of group | −0.02 | 0.23 | −0.08 | 0.935 |
| Group × time interaction | 0.07 | 0.08 | 0.91 | 0.364 |
| IL-4 (pg/ml) | ||||
| Intent-to-treat analysis | ||||
| Time | −2.31 | 0.71 | −3.28 | 0.001 |
| Main effect of group | −0.18 | 2.53 | −0.07 | 0.945 |
| Group × time interaction | 0.49 | 0.99 | 0.49 | 0.625 |
| Per-protocol analysis | ||||
| Time | −1.45 | 0.64 | −2.27 | 0.025 |
| Main effect of group | −0.03 | 2.62 | −0.01 | 0.99 |
| Group × time interaction | −0.32 | 0.89 | −0.36 | 0.719 |